Cargando…

Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain

Neuropathic pain (NPP) is a kind of pain caused by disease or damage impacting the somatosensory system. Ion channel drugs are the main treatment for NPP; however, their irregular usage leads to unsatisfactory pain relief. To regulate the treatment of NPP with ion channel drugs in clinical practice,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Hong, Ma, Ke, Huang, Dong, Liu, Xian-Guo, Liu, Tang-Hua, Liu, Qing, Liu, Guang-Zhao, Song, Tao, Tao, Wei, Wu, Da-Sheng, Wang, Yun-Xia, Yang, Xiao-Qiu, Zhang, Xiao-Mei, Liu, Hui, Liu, Yan-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017507/
https://www.ncbi.nlm.nih.gov/pubmed/33850929
http://dx.doi.org/10.12998/wjcc.v9.i9.2100
_version_ 1783674069075361792
author Xiao, Hong
Ma, Ke
Huang, Dong
Liu, Xian-Guo
Liu, Tang-Hua
Liu, Qing
Liu, Guang-Zhao
Song, Tao
Tao, Wei
Wu, Da-Sheng
Wang, Yun-Xia
Yang, Xiao-Qiu
Zhang, Xiao-Mei
Liu, Hui
Liu, Yan-Qing
author_facet Xiao, Hong
Ma, Ke
Huang, Dong
Liu, Xian-Guo
Liu, Tang-Hua
Liu, Qing
Liu, Guang-Zhao
Song, Tao
Tao, Wei
Wu, Da-Sheng
Wang, Yun-Xia
Yang, Xiao-Qiu
Zhang, Xiao-Mei
Liu, Hui
Liu, Yan-Qing
author_sort Xiao, Hong
collection PubMed
description Neuropathic pain (NPP) is a kind of pain caused by disease or damage impacting the somatosensory system. Ion channel drugs are the main treatment for NPP; however, their irregular usage leads to unsatisfactory pain relief. To regulate the treatment of NPP with ion channel drugs in clinical practice, the Chinese Association for the Study of Pain organized first-line pain management experts from China to write an expert consensus as the reference for the use of ion channels drugs . Here, we reviewed the mechanism and characteristics of sodium and calcium channel drugs, and developed recommendations for the therapeutic principles and clinical practice for carbamazepine, oxcarbazepine, lidocaine, bulleyaconitine A, pregabalin, and gabapentin. We hope this guideline provides guidance to clinicians and patients on the use of ion channel drugs for the management of NPP.
format Online
Article
Text
id pubmed-8017507
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-80175072021-04-12 Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain Xiao, Hong Ma, Ke Huang, Dong Liu, Xian-Guo Liu, Tang-Hua Liu, Qing Liu, Guang-Zhao Song, Tao Tao, Wei Wu, Da-Sheng Wang, Yun-Xia Yang, Xiao-Qiu Zhang, Xiao-Mei Liu, Hui Liu, Yan-Qing World J Clin Cases Expert Consensus Neuropathic pain (NPP) is a kind of pain caused by disease or damage impacting the somatosensory system. Ion channel drugs are the main treatment for NPP; however, their irregular usage leads to unsatisfactory pain relief. To regulate the treatment of NPP with ion channel drugs in clinical practice, the Chinese Association for the Study of Pain organized first-line pain management experts from China to write an expert consensus as the reference for the use of ion channels drugs . Here, we reviewed the mechanism and characteristics of sodium and calcium channel drugs, and developed recommendations for the therapeutic principles and clinical practice for carbamazepine, oxcarbazepine, lidocaine, bulleyaconitine A, pregabalin, and gabapentin. We hope this guideline provides guidance to clinicians and patients on the use of ion channel drugs for the management of NPP. Baishideng Publishing Group Inc 2021-03-26 2021-03-26 /pmc/articles/PMC8017507/ /pubmed/33850929 http://dx.doi.org/10.12998/wjcc.v9.i9.2100 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Expert Consensus
Xiao, Hong
Ma, Ke
Huang, Dong
Liu, Xian-Guo
Liu, Tang-Hua
Liu, Qing
Liu, Guang-Zhao
Song, Tao
Tao, Wei
Wu, Da-Sheng
Wang, Yun-Xia
Yang, Xiao-Qiu
Zhang, Xiao-Mei
Liu, Hui
Liu, Yan-Qing
Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain
title Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain
title_full Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain
title_fullStr Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain
title_full_unstemmed Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain
title_short Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain
title_sort expert consensus of the chinese association for the study of pain on ion channel drugs for neuropathic pain
topic Expert Consensus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017507/
https://www.ncbi.nlm.nih.gov/pubmed/33850929
http://dx.doi.org/10.12998/wjcc.v9.i9.2100
work_keys_str_mv AT xiaohong expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT make expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT huangdong expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT liuxianguo expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT liutanghua expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT liuqing expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT liuguangzhao expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT songtao expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT taowei expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT wudasheng expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT wangyunxia expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT yangxiaoqiu expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT zhangxiaomei expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT liuhui expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain
AT liuyanqing expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain